Sarah R. Verhoeff - Concepedia

Author

Sarah R. Verhoeff

Radboud University Medical Center ORCID

Also Known As

S. R. Verhoeff, S.R. Verhoeff, Sarah R Verhoeff, Sarah R. Verhoeff, Sarah Verhoeff

Publications

359

Citations

H-Index

Concepts

All Affiliations

Radboud University Medical Center Radboud University Nijmegen Vrije Universiteit Amsterdam Amsterdam University Medical Centers University Medical Center Groningen

About

Sarah R. Verhoeff is an author at Radboud University Medical Center specializing in oncology, radiology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	2	2	44
2	Medicine	2	2	44
3	Cancer Therapeutics	2	2	44
4	Immunology	1	1	11
5	Pathology	1	1	11

Sarah R. Verhoeff

Publications

311

Citations

H-Index

Page 1

	Year	Citations
Adjuvant chemotherapy is not associated with improved survival for all high‐risk factors in stage II colon cancer Sarah R. Verhoeff, Felice N. van Erning, V.E.P.P. Lemmens, International Journal of Cancer	2016	127
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma Sarah R. Verhoeff, Suzanne C. van Es, Eline Boon, European Journal of Nuclear Medicine and Molecular Imaging	2019	97
<sup>89</sup>Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer Sarah R. Verhoeff, Pim P. van de Donk, Erik H.J.G. Aarntzen, Journal of Nuclear Medicine Neck CancerOncologic ImagingPd-l1 ExpressionMedicinePd-l1 Imaging	2022	33
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Clinical Cancer Research	2022	31
Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Cancers	2023	12
<sup>89</sup>Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck. Sarah R. Verhoeff, Pim P. van de Donk, Erik H.J.G. Aarntzen, Journal of Clinical Oncology Oncologic ImagingSquamous Cell CarcinomaImmunologyPathologyImmunotherapeutics	2020	11

Page 1